Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0

Genomic alterations and gene expression in primary diffuse large B cell lymphomas of immune privileged sites


ABSTRACT: Primary diffuse large B cell lymphomas of different immune-privileged sites (IP-DLBCL) share many clinical and biological features, such as a relatively poor prognosis, preferential dissemination to other immune-privileged sites and deletion of the HLA region, which suggests that IP-DLBCL represents a separate entity. To further investigate the nature of IP-DLBCL, we investigated site-specific genomic aberrations in 16 testicular, 9 central nervous system (CNS) and 15 nodal DLBCL using array-CGH. We also determined minimal common regions of gain and loss. Using robust algorithms, the array-CGH data were combined with gene expression data to explore pathways deregulated by chromosomal aberrations. Keywords: comparative genomic hybridisation, gene expression, tumor type comparison Whole tissue sections of 16 testicular, 9 central nervous system (CNS) and 15 nodal DLBCL were used for isolation of genomic DNA and total RNA. Genomic aberrations were determined using an in house printed CGH array containing ~3700 large genomic insert clones. Gene expression was analyzed on Affymetrix HU133 plus 2.0 oligo arrays. Gene expression data and arrayCGH data were combined using the R program ACE-it.

ORGANISM(S): Homo sapiens

SUBMITTER: Marije Booman 

PROVIDER: E-GEOD-10524 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

altmetric image

Publications

Genomic alterations and gene expression in primary diffuse large B-cell lymphomas of immune-privileged sites: the importance of apoptosis and immunomodulatory pathways.

Booman M M   Szuhai K K   Rosenwald A A   Hartmann E E   Kluin-Nelemans Hc H   de Jong D D   Schuuring E E   Kluin Pm P  

The Journal of pathology 20081001 2


Primary diffuse large B-cell lymphomas of different immune-privileged sites (IP-DLBCLs) share many clinical and biological features, such as a relatively poor prognosis, preferential dissemination to other immune-privileged sites, and deletion of the HLA region, which suggests that IP-DLBCL represents a separate entity. To further investigate the nature of IP-DLBCL, we investigated site-specific genomic aberrations in 16 testicular, nine central nervous system (CNS), and 15 nodal DLBCLs using ar  ...[more]

Similar Datasets

2008-06-19 | GSE10524 | GEO
2006-05-01 | GSE4296 | GEO
2015-06-02 | GSE69440 | GEO
| EGAS00001005367 | EGA
2009-12-16 | GSE19459 | GEO
2006-04-01 | GSE4157 | GEO
2010-06-25 | E-GEOD-5138 | biostudies-arrayexpress
2010-05-17 | E-GEOD-19459 | biostudies-arrayexpress
2013-04-22 | E-GEOD-36889 | biostudies-arrayexpress
2010-07-05 | GSE9114 | GEO